Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-09-11 DOI:10.1080/17512433.2024.2399073

Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He

{"title":"Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis.","authors":"Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He","doi":"10.1080/17512433.2024.2399073","DOIUrl":null,"url":null,"abstract":"Introduction: Lowering blood glucose is important to prevent long-term microvascular complications in adults with type 2 diabetes mellitus (T2DM). Various evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial for microvascular diseases. This study was designed to investigate whether SGLT2 inhibitors have an effect on eye disorders.Methods: We searched PubMed, Web of Science, and ClinicalTrials.gov for randomized, double-blind, placebo-controlled trials with at least 24 weeks of follow-up up to 20 December 2023. Mantel-Haenszel statistical method, risk ratios (RRs) and 95% confidence intervals (CIs) were used to analyze the binary variables.Results: We included a total of 40 studies covering 104,586 participants. T2DM was present in 84.5% of the subjects. SGLT2 inhibitors had no significant effect on overall eye events compared to placebo (RR 0.99; 95%CI 0.86-1.15; p = 0.91), nor did subgroup analysis. We did not observe significant heterogeneity (I2 = 0; p = 0.99). Analysis of all secondary outcomes showed that SGLT2 inhibitors did not cause a significantly different effect from placebo. Meta-analysis in the entire T2DM population showed results consistent with those in the overall population.Conclusion: SGLT2 inhibitors did not have a significant effect on eye disorders during treatment, regardless of baseline conditions and duration of treatment.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2024.2399073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lowering blood glucose is important to prevent long-term microvascular complications in adults with type 2 diabetes mellitus (T2DM). Various evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial for microvascular diseases. This study was designed to investigate whether SGLT2 inhibitors have an effect on eye disorders.

Methods: We searched PubMed, Web of Science, and ClinicalTrials.gov for randomized, double-blind, placebo-controlled trials with at least 24 weeks of follow-up up to 20 December 2023. Mantel-Haenszel statistical method, risk ratios (RRs) and 95% confidence intervals (CIs) were used to analyze the binary variables.

Results: We included a total of 40 studies covering 104,586 participants. T2DM was present in 84.5% of the subjects. SGLT2 inhibitors had no significant effect on overall eye events compared to placebo (RR 0.99; 95%CI 0.86-1.15; p = 0.91), nor did subgroup analysis. We did not observe significant heterogeneity (I² = 0; p = 0.99). Analysis of all secondary outcomes showed that SGLT2 inhibitors did not cause a significantly different effect from placebo. Meta-analysis in the entire T2DM population showed results consistent with those in the overall population.

Conclusion: SGLT2 inhibitors did not have a significant effect on eye disorders during treatment, regardless of baseline conditions and duration of treatment.

查看原文本刊更多论文

钠-葡萄糖共转运体 2 抑制剂与眼疾之间的关系：系统回顾和荟萃分析。

简介降低血糖对于预防成人 2 型糖尿病（T2DM）患者的长期微血管并发症非常重要。各种证据表明，钠-葡萄糖共转运体 2（SGLT2）抑制剂对微血管疾病有益。本研究旨在探讨 SGLT2 抑制剂是否对眼部疾病有影响：我们在PubMed、Web of Science和ClinicalTrials.gov上检索了截至2023年12月20日至少随访24周的随机、双盲、安慰剂对照试验。采用曼特尔-海恩泽尔统计方法、风险比（RR）和95%置信区间（CI）分析二元变量：我们共纳入了 40 项研究，覆盖 104 586 名参与者。84.5%的受试者患有 T2DM。与安慰剂相比，SGLT2 抑制剂对总体眼部事件没有显著影响（RR 0.99；95%CI 0.86-1.15；P = 0.91），亚组分析也是如此。我们没有观察到明显的异质性（I2 = 0；P = 0.99）。对所有次要结果的分析表明，SGLT2 抑制剂与安慰剂的效果没有明显差异。对所有 T2DM 患者进行的 Meta 分析表明，结果与整个人群的结果一致：结论：无论基线条件和疗程长短如何，SGLT2 抑制剂在治疗期间都不会对眼部疾病产生显著影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.